CA2309761A1 - Appauvrissement de la cellule th2, compositions et methodes en rapport - Google Patents

Appauvrissement de la cellule th2, compositions et methodes en rapport Download PDF

Info

Publication number
CA2309761A1
CA2309761A1 CA002309761A CA2309761A CA2309761A1 CA 2309761 A1 CA2309761 A1 CA 2309761A1 CA 002309761 A CA002309761 A CA 002309761A CA 2309761 A CA2309761 A CA 2309761A CA 2309761 A1 CA2309761 A1 CA 2309761A1
Authority
CA
Canada
Prior art keywords
ccr8
cells
binding
antagonist
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002309761A
Other languages
English (en)
Inventor
Hortensia Soto-Trejo
Joseph A. Hedrick
Monica Napolitano
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2309761A1 publication Critical patent/CA2309761A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention, qui a trait à des compositions de liaison se liant de manière sélective à un marqueur présent de manière spécifique sur des cellules Th2, concerne également diverses méthodes d'utilisation de ces compositions. La méthode fait, notamment, usage du fait que le récepteur de chémokine CCR8 est exprimé de manière sélective dans le sous-ensemble de cellule Th2. La composition de liaison est, de préférence, un anticorps monoclonal spécifique de CCR8.
CA002309761A 1997-11-13 1998-11-12 Appauvrissement de la cellule th2, compositions et methodes en rapport Abandoned CA2309761A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6539297P 1997-11-13 1997-11-13
US60/065,392 1997-11-13
PCT/US1998/023240 WO1999025734A2 (fr) 1997-11-13 1998-11-12 APPAUVRISSEMENT DE LA CELLULE Th2, COMPOSITIONS ET METHODES EN RAPPORT

Publications (1)

Publication Number Publication Date
CA2309761A1 true CA2309761A1 (fr) 1999-05-27

Family

ID=22062409

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002309761A Abandoned CA2309761A1 (fr) 1997-11-13 1998-11-12 Appauvrissement de la cellule th2, compositions et methodes en rapport

Country Status (7)

Country Link
EP (1) EP1030865A2 (fr)
JP (1) JP2001523446A (fr)
AR (1) AR016681A1 (fr)
AU (1) AU1373099A (fr)
CA (1) CA2309761A1 (fr)
WO (1) WO1999025734A2 (fr)
ZA (1) ZA9810371B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416954B1 (en) * 1999-02-08 2002-07-09 Schering Corporation Modulating Th2 cell levels via vMIP-I/CCR8 interaction
WO2001058484A2 (fr) * 2000-02-10 2001-08-16 Schering Corporation Nouvelles utilisations des recepteurs ccr8 de mammiferes et reactifs associes
US6762341B2 (en) 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
AU2003229753A1 (en) * 2002-05-13 2003-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2007044756A2 (fr) * 2005-10-11 2007-04-19 Icos Corporation Anticorps monoclonaux reconnaissant le ccr8 humain
WO2014082993A2 (fr) * 2012-11-30 2014-06-05 Galapagos Nv Cibles moléculaires et composés, et procédés d'identification de ceux-ci, utiles dans la régulation à la baisse de la réponse th2
JP7358047B2 (ja) * 2016-05-16 2023-10-10 チェックマブ エス．アール．エル． 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー
CA3124332A1 (fr) * 2018-12-27 2020-07-02 Shionogi & Co., Ltd. Nouvel anticorps anti-ccr8
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
WO2023219147A1 (fr) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Nouveaux anticorps anti-ccr8 pour la détection de ccr8

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
EP0843557B1 (fr) * 1995-07-21 2002-11-13 Applied Research Systems ARS Holding N.V. Procedes pour detecter, identifier, isoler, marquer et cibler selectivement les lymphocytes th1, au moyen de la proteine lag-3
US6040426A (en) * 1996-06-05 2000-03-21 Bml, Inc. Human Th2 specific protein

Also Published As

Publication number Publication date
EP1030865A2 (fr) 2000-08-30
AU1373099A (en) 1999-06-07
WO1999025734A2 (fr) 1999-05-27
JP2001523446A (ja) 2001-11-27
ZA9810371B (en) 1999-08-30
AR016681A1 (es) 2001-07-25
WO1999025734A3 (fr) 1999-07-15

Similar Documents

Publication Publication Date Title
US7521045B2 (en) Methods of inhibiting metastasis
AU773293B2 (en) Anti-CCR4 antibodies and methods of use therefor
JP5215723B2 (ja) 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
JP2014028860A (ja) 転移を阻害する方法
JP2000514295A (ja) 哺乳動物のケモカイン試薬
CA2309761A1 (fr) Appauvrissement de la cellule th2, compositions et methodes en rapport
US6676939B2 (en) Methods of modulating IL-174 response
JP4263391B2 (ja) 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
JP2002540068A (ja) 治療におけるｍｉｐ−３ａのアゴニストまたはアンタゴニストの使用
US6645491B1 (en) Method for treating inflammatory conditions using an antibody to MIP-3α
US7208152B2 (en) Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
US6207155B1 (en) Method of eosinophil depletion with antibody to CCR 3 receptor
CA2256459A1 (fr) Agonistes interleukine-4 selectifs vis-a-vis des lymphocytes t
US6824781B2 (en) Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist
US6416954B1 (en) Modulating Th2 cell levels via vMIP-I/CCR8 interaction
MXPA00004667A (en) Th2 CELL DEPLETION;COMPOSITIONS;METHODS
CA2288017A1 (fr) Methodes relatives a un appauvrissement des eosinophiles et compositions afferentes
MXPA99010259A (en) Methods for eosinophil depletion and compositions therefor
MXPA01007938A (en) Use of agonists or antagonists of mip-3a in therapy
MXPA01007199A (en) Anti-ccr4 antibodies and methods of use therefor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued